Bioinvent International Ab Stock Performance
| BOVNF Stock | USD 3.29 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and BioInvent International are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days BioInvent International AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, BioInvent International is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 729.3 M | |
| Total Cashflows From Investing Activities | -467.5 M |
BioInvent |
BioInvent International Relative Risk vs. Return Landscape
If you would invest 329.00 in BioInvent International AB on November 15, 2025 and sell it today you would earn a total of 0.00 from holding BioInvent International AB or generate 0.0% return on investment over 90 days. BioInvent International AB is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than BioInvent, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
BioInvent International Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioInvent International for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioInvent International can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BioInvent International generated a negative expected return over the last 90 days | |
| BioInvent International has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 19.38 M. Net Loss for the year was (278.44 M) with profit before overhead, payroll, taxes, and interest of 19.38 M. | |
| BioInvent International AB has accumulated about 12.18 M in cash with (245.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| Roughly 57.0% of the company shares are held by institutions such as insurance companies |
BioInvent International Fundamentals Growth
BioInvent Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BioInvent International, and BioInvent International fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioInvent Pink Sheet performance.
| Return On Equity | -0.0274 | |||
| Return On Asset | -0.0192 | |||
| Profit Margin | (0.14) % | |||
| Current Valuation | 183.41 M | |||
| Shares Outstanding | 65.8 M | |||
| Price To Earning | (8.68) X | |||
| Price To Book | 2.32 X | |||
| Price To Sales | 11.53 X | |||
| Revenue | 19.38 M | |||
| EBITDA | (263.32 M) | |||
| Cash And Equivalents | 12.18 M | |||
| Cash Per Share | 0.04 X | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (245.84 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 1.45 B | |||
About BioInvent International Performance
By analyzing BioInvent International's fundamental ratios, stakeholders can gain valuable insights into BioInvent International's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioInvent International has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioInvent International has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioInvent International AB , a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. The Company was incorporated in 1996 and is based in Lund, Sweden. Bioinvent International operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 84 people.Things to note about BioInvent International performance evaluation
Checking the ongoing alerts about BioInvent International for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BioInvent International help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioInvent International generated a negative expected return over the last 90 days | |
| BioInvent International has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 19.38 M. Net Loss for the year was (278.44 M) with profit before overhead, payroll, taxes, and interest of 19.38 M. | |
| BioInvent International AB has accumulated about 12.18 M in cash with (245.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| Roughly 57.0% of the company shares are held by institutions such as insurance companies |
- Analyzing BioInvent International's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioInvent International's stock is overvalued or undervalued compared to its peers.
- Examining BioInvent International's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioInvent International's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioInvent International's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioInvent International's pink sheet. These opinions can provide insight into BioInvent International's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioInvent Pink Sheet analysis
When running BioInvent International's price analysis, check to measure BioInvent International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioInvent International is operating at the current time. Most of BioInvent International's value examination focuses on studying past and present price action to predict the probability of BioInvent International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioInvent International's price. Additionally, you may evaluate how the addition of BioInvent International to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |